Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Robotics & AI Drive Tech Resurgence in Q2 Despite Economic Headwinds

BY | ETF Database
4:58 am ET 07/16/25 | 84 VIEWS
The technology sector experienced a powerful resurgence in growth in the second quarter of 2025, driven by strength in robotics, artificial intelligence (AI), and healthcare technology. This impressive performance comes amidst a complex global economic landscape, as the World Bank recently downgraded its 2025 global growth outlook. Despite lingering global economic uncertainties and persistent tariff concerns, the ROBO Global index family recorded significant gains, signaling a broader renaissance in transformative technologies poised to reshape industries worldwide. The ROBO Global Robotics and Automation Index (ROBO B-) stood out for its performance, which surged by 16.5% in the second quarter. This broad-based rally, with positive returns across all 11 subsectors, marks a notable shift in sentiment for the robotics industry. This turnaround can be attributed to strong demand for automation, driven by accelerating global industrial modernization and ongoing reshoring efforts, according to Zeno Mercer, senior research analyst at VettaFi. The manufacturing and industrial automation segment saw an 18.4% gain. The growing use of automation to remain competitive amidst rising labor expenses and increasingly intricate supply chains has driven strength in the sector. Additionally, logistics automation recorded a 25% gain, fueled by Symbotic’s 92.2% jump. Discussions between Toyota Industries and Toyota Motors for a potential $30+ billion acquisition further underscore logistics automation’s strategic value. Furthermore, the autonomous systems subsector delivered a 45.8% return during the quarter, with category names Serve Robotics and Joby Aviation climbing more than 75% each. This highlights the growing commercial viability of autonomous technologies across multiple domains, according to Mercer. Finally, the healthcare subsector managed a modest 1.2% gain, facing headwinds from declines in companies like Azenta and Globus Medical. Tariff uncertainties continue to impact this segment, though fundamental growth drivers persist. Automation solutions have the potential to help global healthcare systems address persistent labor shortages. Looking for regular updates? Subscribe here for weekly insights on robotics, AI, and healthcare technology, delivered straight to your inbox. For more news, information, and analysis, visit our Disruptive Technology Content Hub. ROBO is the underlying index for the ROBO Global Robotics & Automation ETF (ROBO), the L&G ROBO Global Robotics and Automation UCITS ETF (ROBO.LN), and the Global X ROBO Global Robotics & Automation ETF (ROBO.AU). VettaFi is the index provider for the ROBO ETFs, for which it receives an index licensing fee. However, the ROBO ETFs are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of the ROBO ETFs.

More Commentary

Weathering the Storm: Case for Low Volatility ETFs
BY | ETF Database
6:06 am ET 07/16/25 | 56 VIEWS
Top Performing Leveraged/Inverse ETFs: 07/13/2025
BY | ETF Database
07/15/2025 | 196 VIEWS
Approach China Exposure Via Defined Outcome ETFs
BY | ETF Database
07/15/2025 | 165 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.